Imagine your body has a set of 'master blueprints' used to build your brain and nerves when you were an embryo. Some of these blueprints stay active in adults to help repair and protect cells. This project uses a specific protein from those blueprints to act like a rescue team for dying nerve cells in the spinal cord.
ALS is a devastating disease with a short life expectancy of 2-5 years and no effective treatment to stop its progression. There is a critical market gap for disease-modifying therapies that can rescue motor neurons.
A therapeutic candidate using the Engrailed-1 (hEN1) homeoprotein. The project completed animal toxicity studies confirming the product's good tolerability profile.
If you are a drug development firm dealing with the lack of effective ALS treatments — this project developed a therapy using the Engrailed-1 protein that rescues spinal motor neurons in preclinical models. This could lead to a disease-modifying treatment requiring only a few injections per year.
If you are a care provider dealing with the rapid progression of ALS where patients live only 2-5 years after diagnosis — this project developed a protein-based therapy that has shown good tolerability in animal toxicity studies. This offers a path toward slowing disease progression for your patient base.
If you are a manufacturer dealing with the need for high-stability therapeutic proteins — this project developed a method to use homeoproteins like hEN1 that remain active for several months after a single injection. This reduces the frequency of administration for the end user.
Based on available project data, the cost per treatment or pricing strategy is not specified.
Based on available project data, the project focuses on preclinical toxicity and validation; industrial scaling details are not provided.
Based on available project data, the technology is being developed by BrainEver, but specific patent or licensing terms are not listed.
The project conducted a toxicity evaluation in animals as a prerequisite required by health authorities to allow human clinical trials.
The project has completed animal toxicity studies in 2023, with the goal of moving toward future clinical trials in patients living with ALS.
The project is led by a single SME, BrainEver (France), which holds 100% of the industry ratio. This indicates a highly centralized, agile development process where the commercial entity directly controls the research and development of the homeoprotein platform.
Contact BrainEver in France
Contact us to explore licensing opportunities for homeoprotein-based neuro-therapies.
